SML0710

DDRI-18

≥98% (HPLC)

• Synonym(e): 3,3′-[6,6′-bi-1H-Benzimidazole]-2,2′-diylbis-benzenamine
• Empirische Formel (Hill-System): C₂₆H₂₀N₆
• CAS-Nummer: 4402-18-0
• Molekulargewicht: 416.48
• NACRES: NA.77
• PubChem Substance ID: 329825588
• UNSPSC Code: 12352200
• MDL number: MFCD01137750
• eCl@ss: 32150313
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 10 mg/mL
• storage temp.: 2-8°C
• SMILES string: NC1=CC=CC(C(N2)=NC(C=C3)=C2C=C3C4=CC5=C(C=C4)N=C(N5)C6=CC(N)=CC=C6)=C1
• InChI: 1S/C26H20N6/c27-19-5-1-3-17(11-19)25-29-21-9-7-15(13-23(21)31-25)16-8-10-22-24(14-16)32-26(30-22)18-4-2-6-20(28)12-18/h1-14H,27-28H2,(H,29,31)(H,30,32)
• InChI key: QROWVLFOWUYBIG-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

DDRI-18 (DNA Damage Response Inhibitor-18) inhibits nonhomologous end-joining (NHEJ) DNA repair following double strand DNA breaks induced by ionizing radiation, and enhances the effects of DNA-damaging cancer drugs like etoposide, camptothecin and doxorubicin.

DDRI-18 (DNA Damage Response Inhibitor-18) inhibits nonhomologous end-joining (NHEJ) DNA repair.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• Gefahrencodes: H315,H319,H335,H413
• Sicherheitshinweise: P261 - P264 - P271 - P273 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• Zielorgane: Respiratory system
• Lagerklasse: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable